Voyager Therapeutics (VYGR) Peer Comparison

$3.51

$0.13 (3.85%)

As on 04-Sep-2026 16:25EDT

Market cap

$216 Mln

Revenue (TTM)

$34 Mln

P/E Ratio

--

P/B Ratio

1.3

Div. Yield

0 %

Edit

	Voyager Therapeutics (VYGR)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	216	16,504	17,747	14,622	12,501
Revenue ($ Mln)	34	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-107.73	491.50	755.85	860.62	-325.10
Net Margin (%)	-312.63	17.67	71.69	35.33	-25.32
RoE (%)	-61.48	110.09	--	42.98	-57.72
Price to Earnings	--	34.72	20.93	18.56	--
Price-To-Book	1.34	38.18	10.51	7.95	23.94

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Voyager Therapeutics (VYGR)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	34.46	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	70.35	1,982.07	103.47	85.67	109.42
Gross Profit	-91.90	760.62	588.53	2,236.43	902.26
Operating Expenses	81.30	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-117.19	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-107.60	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.13	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-107.73	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Voyager Therapeutics (VYGR)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	154.38	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	26.69	187.89	384.48	288.55	346.72
Current Liabilities	16.69	1,435.43	464.70	361.93	374.20
Total Liabilities	252.28	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Voyager Therapeutics (VYGR)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	72.53	1,006.90	895.24	1,243.41	45.47
Current Assets	125.23	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	252.28	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	32.57	120.10	449.89	165.93	347.75
Net Current Assets	108.54	-385.14	925.52	888.90	824.98

Cashflow ($ Mln)

	Voyager Therapeutics (VYGR)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-132.47	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	125.45	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	0.82	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Voyager Therapeutics (VYGR)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-41.57	53.56	-30.01	32.82	-31.49
ROE (%)	-61.48	110.09	163.18	42.98	-57.72
ROA (%)	-37.24	15.64	31.68	29.32	-22.97
EBIT Margin (%)	-312.26	21.13	5.73	31.04	-18.97
Net Margin (%)	-312.63	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Voyager Therapeutics (VYGR)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	-19.07	24.67	114.85	9.23	149.04
EBIT Growth (%)	-0.32	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	0.19	17.50	378.76	42.89	-15.32
EPS Growth (%)	1.97	26.84	353.27	50.42	-0.64
Book Value Growth (%)	-38.68	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Voyager Therapeutics (VYGR)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-1.93	36.06	-59.76	15.79	-45.32
Price / Book Value	1.34	38.18	10.51	7.95	23.94
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-0.55	27.00	230.43	13.21	-39.74
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Voyager Therapeutics (VYGR)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.27	0.00	0.65
Short term debt to equity ratio	0.04	0.00	0.05	0.00	0.00
Current Ratio	7.51	0.73	2.99	3.46	3.20
Quick Ratio	7.51	0.73	2.32	3.38	2.94
Interest Coverage	--	--	1.62	--	-9.32

Operating Efficiency Ratios

	Voyager Therapeutics (VYGR)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	9.15	15.88	21.25	13.74	14.98
Asset Turnover	0.12	0.89	0.44	0.83	0.91
Receivable days	28.28	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	12.44	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly